References
- Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011;152:52-60
- Psaila B, Ptrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009;114:4777-83
- Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711-2
- Amgen to Discuss Romiplostim Application at FDA ODAC Meeting. Thousand Oaks, CA: Amgen Inc, 2008. http://www.drugs.com/nda/romiplostim_080312.html. Accessed July 17, 2012
- Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8
- Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
- Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
- Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-99
- Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-71
- Pullarkat VA, Gernsheimer TB, Wasser JS, et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol 2009;84:538-40
- Zeng Y, Duan X, Xu J, et al. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Coch Database Syst Rev 2011;7:CD008235
- Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. Am J Hematol 2012;87:984-7
- L’Institut national d’excellence en santé et en services sociaux (INESSS). Avis au ministre. Québec, Canada: NPlate, 2010. http://www.inesss.qc.ca/index.php?id=72&user_inessscapsules_pi1%5Buid%5D=829&user_inessscapsules_pi1%5Bonglet%5D=3&user_inessscapsules_pi1%5BbackUrl%5D=index.php%253Fid%253D42%2526no_cache%253D1%2526user_inessscapsules_pi1%25255Bterme%25255D%253Dromiplostim%2526user_inessscapsules_pi1%25255Bonglet%25255D%253D3%2526user_inessscapsules_pi1%25255BEVALUES_pointer%25255D%253D0%2526user_inessscapsules_pi1%25255Bsubmit%25255D%253DRechercher&cHash=f25e4fa050e25e92f60b1ce1363f9bfb. Accessed November 8, 2012
- Institute national d’excellence en santé et en services sociaux. Formulary Registration Application. Gouvernement du Québec: Québec, Canada, June 1, 2010 http://www.inesss.qc.ca/index.php?id=38&L=1. Accessed October 24, 2012
- Amgen Canada Inc. Nplate® (romiplostim) Product Monograph, Mississauga, Canada, 2011
- Bussell JB. Maintenance treatment of adults with chronic refractory immune thrombocytopenia purpura using repeated intravenous infusions of gammaglobulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 1989;53:S147-55
- Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2 year results of 72 adults in a romiplostim compassionate-use program. Blood 2011;118:4338-45
- Wilson K, Hébert PC. The challenge of an increasingly expensive blood system. Can Med Assoc J 2003;168:1149-50